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Ubiquitination has been demonstrated to play a pivotal role in multiple biological func-
tions, which include cell growth, proliferation, apoptosis, DNA damage response, innate
immune response, and neuronal degeneration. Although the role of ubiquitination in tar-
geting proteins for proteasome-dependent degradation have been extensively studied and
well-characterized, the critical non-proteolytic functions of ubiquitination, such as protein
trafﬁcking and kinase activation, involved in cell survival and cancer development, just
start to emerge, In this review, we will summarize recent progresses in elucidating the
non-proteolytic function of ubiquitination signaling in protein kinase activation and its impli-
cations in human cancers. The advancement in the understanding of the novel functions
of ubiquitination in signal transduction pathways downstream of growth factor receptors
may provide novel paradigms for the treatment of human cancers.
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INTRODUCTION
Posttranslational modiﬁcation of cellular proteins, such as phos-
phorylation, ubiquitination, SUMOylation, PARylation, to name
a few, have been shown to play a pivotal role in multiple cellular
processes such as proliferation, apoptosis, senescence, autophagy,
DNA damage repair, innate immune response, and neuron degen-
eration (Kim et al., 2008b; Kirkin et al., 2009; Kraft et al., 2010; Gao
et al., 2011). Ubiquitination is originally described as a process
by which ubiquitin is covalently attached to the lysine residue of
a target protein for proteasome-mediated degradation by three
enzymes, namely E1 (ubiquitin-activating enzyme), one of many
E2s (ubiquitin-conjugating enzymes, UBCs), and one of many
E3s (ubiquitin ligases; Bhoj and Chen, 2009; Figure 1). As ubiq-
uitination is a reversible process, ubiquitin covalently attached
to a target protein can be removed by deubiquitinating enzymes
(DUBs; Figure 1). Thus the balance between the activities of ubiq-
uitin enzymes and DUBs determines the level and activity of a
target protein.
Although ubiquitination most often lead to proteasome-
mediated degradation of the target protein (Pickart, 2001; Weiss-
man et al., 2011), recent evidence suggests non-proteolytic func-
tions for ubiquitination in the regulation of protein subcellular
localization and activity (Giasson and Lee, 2003; Bhoj and Chen,
2009; Chen and Sun, 2009; Hoeller and Dikic, 2009; Raiborg
and Stenmark, 2009; de Bie and Ciechanover, 2011). These novel
ﬁndings suggest that posttranslational modiﬁcation of protein
by ubiquitin and ubiquitin-like proteins is involved in a much
wider range of cellular processes and signal transduction pathways
important for numerous biological functions.
In this review, we will focus on the recent advances in the novel
role of ubiquitination in theNF-κB activation and PKB/Akt kinase
activation and their implications in human cancers. In addition,
we will discuss some potential therapeutic strategies for targeting
the ubiquitination pathways in the treatment of human cancers.
UBIQUITIN–PROTEASOME SYSTEM
A large number of proteins are posttranslational modiﬁed by
ubiquitin. Ubiquitin, a 76-amino acid protein, is highly evolu-
tionarily conserved across species. In the ubiquitination process,
ubiquitin is covalently conjugated to lysine residues of substrate
proteins through a three-step enzymatic reaction. Ubiquitin is ﬁrst
activated by ubiquitin-activating enzyme (E1). The activated ubiq-
uitin is then delivered to the ubiquitin-conjugating enzyme (E2),
and will be transferred from the E2 to a lysine residue of a target
protein by ubiquitin ligase (E3; Figure 1B).
As a general principle, the ubiquitin-conjugating enzyme E2
determines the type of ubiquitination modiﬁcation to occur and
the ubiquitin ligase E3 confers substrate speciﬁcity. Currently,
there are two E1s, 50 E2s, and 600 E3s identiﬁed in human
genome (Bhoj and Chen, 2009). There are seven lysine (K)
residues (K6, K11, K27, K29, K33, K48, and K63) in the ubiqui-
tin, which have been identiﬁed to be utilized for ubiquitination
chains (Figure 1A). Most E2s trigger the K48-linked ubiquiti-
nation, in turn leading to proteasome-dependent degradation.
However, the functions of ubiquitin conjugation are not limited
to the ubiquitin–proteasome pathway. Mono and polyubiquitins
are used as signals in various pathways including endocytosis,
DNA repair, apoptosis, and transcriptional regulation. Polyubiq-
uitin chains can be formed using lysine residues other than K48,
the linkage required for proteasomal degradation (Figure 1B).
Ubiquitin-conjugating enzyme 13 is a major E2 that induces
K63-linked ubiquitination with the assistance of its cofactor
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FIGURE 1 | (A) Ubiquitin, a 76-amino acid protein, is highly evolutionarily
conserved across species. It contains seven lysine (K) residues (K6, K11, K27,
K29, K33, K48, and K63) in the ubiquitin, which have been identiﬁed to be
utilized for ubiquitination chains. (B) In the ubiquitination process, ubiquitin is
covalently conjugated to lysine residues of substrate proteins through a
three-step enzymatic reaction. Ubiquitin is ﬁrst activated by
ubiquitin-activating enzyme (E1). The activated ubiquitin is then delivered to
the ubiquitin-conjugating enzyme (E2), which will be transferred from the E2
to a lysine residue of a target protein by ubiquitin ligase (E3). The function
usefulness of ubiquitin conjugation is not limited to the ubiquitin–proteasome
pathway. Mono- and polyubiquitins are used as signals in various pathways
including endocytosis, DNA repair, apoptosis, and transcriptional regulation.
UEV1A. In stark contrast to the role of K48-linked ubiquitina-
tion in targeting its substrate protein for proteasome-degradation,
the K63-linked ubiquitination does not induce proteasome-
dependent degradation, but serves as a molecular platform for
protein/protein interaction important for kinase signaling activa-
tion, receptor endocytosis, protein trafﬁcking, and DNA damage
repair. Although other types of ubiquitination modiﬁcations are
also observed, the exact role that they play is unclear. Recent stud-
ies suggest that they can be involved in protein degradation or
non-proteolytic functions (Figure 1B; Adhikari and Chen, 2009;
Heemers and Tindall, 2009; Xu et al., 2009).
The E3s fall into two major families: E3s with HECT (homolo-
gous to the E6-AP carboxyl terminus) domain and E3s with RING
(a really interesting new gene) or RING-like domain (e.g., U-Box
and PHD domain; Bhoj and Chen, 2009). There are ∼600 RING
ﬁnger and ∼30 HECT ligases in the human genome. Most of E3s
recognize substrate proteins for K48-linked ubiquitination. How-
ever, several E3s can target proteins for K63-linked ubiquitination,
such asHectH9,Mdm2,TNF receptor-associated factor 6 (TRAF6;
tumor necrosis factor receptor-associated factor 6), cIAP1/2 (cel-
lular inhibitor of apoptosis protein 1/2), CHIP, Parkin, UCHL1,
TRAF2, ITCH, and NEDD4-2 (Adhikary et al., 2005; Huen et al.,
2007; Mailand et al., 2007; Bertrand et al., 2008; Bhoj and Chen,
2009; Lim and Lim, 2011). Interestingly, HectH9, Mdm2, RNF8
(ringﬁnger protein 8),and cIAP1/2 can trigger bothK63- andK48-
linked ubiquitination. For example, HectH9 not only targets Myc
for K63-linked ubiquitination, which is critical for Myc transcrip-
tional activation and the expression of a subset of Myc target genes,
but also target MCL-1 and p19Arf for ubiquitination-dependent
degradation (Adhikary et al., 2005; Chen et al., 2005; Zhong et al.,
2005). So far, TRAF6 and RNF168 are the only two known E3s that
selectively target substrate proteins for K63-linked ubiquitination,
and thus play an important role in the innate immune response,
DNA damage response (DDR), and tumorigenesis (Huen et al.,
2007; Mailand et al., 2007; Bhoj and Chen, 2009).
THE DEUBIQUITINATING ENZYMES
Protein ubiquitination is a reversible process, and it is tightly con-
trolled at both the levels of ubiquitin-conjugation and ubiquitin-
deconjugation. Removal of ubiquitin on proteins is carried out by
the DUBs. There are at least 98 DUBs encoded in the human
genome, which can subdivided into six subfamilies based on
sequence and structural similarity: ubiquitin-speciﬁc proteases
(USP), ubiquitin carboxyl-terminal hydrolases (UCH), ovar-
ian tumor-like proteases (OTU), JAMM/MPN metalloproteases,
Machado–Jakob-disease (MJD) proteases, and the recently dis-
covered monocyte chemotactic protein-induced protein (MCPIP)
family (Sun, 2008; Bhoj and Chen, 2009; Hoeller and Dikic, 2009;
Liang et al., 2010; Fraile et al., 2011).Onemechanism to control the
activities of DUB is the substrate speciﬁcity, the type of ubiquitin-
chain linkages that are processed. Structural and functional studies
have suggested that USPs and OTUs recognize and remove either
Lys48- or Lys63-linked polyubiquitin chains. For example, USP14
removes Lys48-linked chains (Hu et al., 2005),whereas CYLD only
efﬁciently processes Lys63 linkages and linear ubiquitin chains
(Komander et al., 2009). Some OTU family components such as
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OTUB1 and A20 hydrolyze Lys48-linked chains, whereas TRA-
BID and OTUD5 have preference for Lys63 linkages (Virdee et al.,
2010). Furthermore, Cezanne, suppressesing NF-κB activation by
targeting RIP1 for deubiquitination (Enesa et al., 2008), prefer-
entially cleaves Lys11 over Lys48 and Lys63 linkages (Bremm et
al., 2010), whereas JAMMs share the speciﬁcity for Lys63-linked
polyubiquitin (McCullough et al., 2004; Sato et al., 2008; Cooper
et al., 2009). Finally, the Josephin ATXN3-editing activity shows a
restricted speciﬁcity for K63-linked chains (Winborn et al., 2008).
The activity of DUBs regulates the turnover rate, activation, recy-
cling, and localization of multiple proteins, and thus plays an
essential role in cell homeostasis, protein stability, and a wide
range of signaling pathways (Table 1) (Cohn et al., 2007; Shao
et al., 2009; Lee et al., 2010; Nakada et al., 2010; Wiltshire et al.,
2010). Importantly, deregulated DUB function has been linked to
several diseases, including cancer (Table 1) (Nicassio et al., 2007;
Bhoj and Chen, 2009; Novak et al., 2009; Fraile et al., 2011; Luise
et al., 2011; Metzig et al., 2011).
EMERGING ROLES FOR K63-UBIQUITINATION IN NF-κB
ACTIVATION, AND KINASE ACTIVATION
K63-UBIQUITINATION PLAYS AN IMPORTANT ROLE IN NF-κB
ACTIVATION AND INFLAMMATION
Emerging evidence suggests that K63-linked ubiquitination also
plays a pivotal role in the regulation of pathways that have been
implicated in inﬂammatory response and cancer development,
such as NF-κB (Skaug et al., 2009). The canonical NF-κB acti-
vation pathway is mediated through IKK, an upstream kinase
responsible for IκB phosphorylation and subsequent degrada-
tion (Figure 2). IKK is consisted of IKKα kinase, IKKβ kinase,
and IKKγ regulatory subunit (also known as NEMO; Chen, 2005;
Bhoj and Chen, 2009; Skaug et al., 2009), which phosphorylates
IκB and promotes SCF-βTrCP-mediated K48-linked ubiquitina-
tion and subsequent degradation by proteasome. Degradation of
IκB results in NF-κB nuclear translocation and activation. In the
non-canonical pathway, NIK-mediated-phosphorylation of IKKα
results in its activation and subsequent phosphorylation of p100,
which recruits a K48 E3 ligase to targetp100 for partial proteaso-
mal degradation (Martinez-Forero et al., 2009; Skaug et al., 2009).
A stop signal within the p100 sequence will terminate the pro-
teasomal degradation process and the p52 transcription factor is
then released and forms heterodimer NF-κB2 transcription factor
with REL-B, which translocates to the nucleus and regulates gene
expression. K63-linked ubiquitination has been shown to play
an important role in both canonical and non-canonical NF-κB
activation pathways (Figure 2).
In both canonical and non-canonical NF-κB pathways, the
engagement of cell surface receptors, such as TNFR, IL-1R, Toll-
like receptor (TLR), and CD40 by ligand stimulation, leads to
the recruitment of the TRAFs such as TRAF2 and TRAF6, to
the receptors (Skaug et al., 2009; Figure 2). TRAF proteins are
ubiquitin ligases containing a highly conserved N-terminal RING
domain except for TRAF1. TRAF6 has been demonstrated to play
an important role in innate immune response and apoptosis by
regulating TLR and TGF-β signaling involved in NF-κB activation
and p38 activation, respectively (Chen, 2005; Sorrentino et al.,
2008; Yamashita et al., 2008; Heldin et al., 2009; Skaug et al., 2009).
In the canonical pathways, after ligand binding to IL-1R or
TLRs, the adaptor protein MyD88 is recruited to the cytoplas-
mic tail of the receptor and facilitates its interaction with IRAK4
and IRAK1 serine/threonine protein kinases. IRAK4 in turn
phosphorylates and activate IRAK1 (Ordureau et al., 2008), which
Table 1 | Deubiquitinating enzymes (DUBs) play important roles in NF-κB activation, DNA damage response, and cancer.
DUBs Substrates Function Role in cancer References
A20 IKKγ/NEMO, RIP1,
TRAF6, MALT1
Negatively regulates the NF-κB
pathway
Tumor suppressor Mauro et al. (2006), Sun (2008), Kato
et al. (2009), Novak et al. (2009),
Compagno et al. (2009), Bhoj and Chen
(2009)
CYLD IKKγ/NEMO
TRAF2, RIP1,
TAK1, BCI3
Negatively regulates the NF-κB
pathway
Tumor suppressor Brummelkamp et al. (2003), Kovalenko
et al. (2003), Sun (2008), Sun (2010),
Bhoj and Chen (2009)
Cezanne RIP1 Negatively regulates the NF-κB
pathway
Unknown Enesa et al. (2008)
USP2 Unknown Positively regulates the NF-κB
pathway
Downregulated in breast cancer Metzig et al. (2011)
USP3 H2A, H2B Required for DSB repair Unknown Nicassio et al. (2007)
USP11 Unknown, IκBα Regulates HR pathway;
Negatively regulates NF-κB
pathway
Overexpressed in malignant
melanoma, associated with a more
aggressive & invasive phenotype
Wiltshire et al. (2010), Luise et al. (2011)
BRCC36 γH2AX Regulates DSB repair pathway Unknown Shao et al. (2009)
OTUB1 Unknown Regulates DSB pathway by
Inhibit RNF168 activity
Unknown Nakada et al. (2010)
USP1 FANCI–FANCD2, PCNA Negatively regulates ICL repair Unknown Cohn et al. (2007), Lee et al. (2010)
USP3, ubiquitin-speciﬁc peptidase 3; CYLD, cylindromatosis tumor suppressor; ICL, interstrand crosslink repair; BRCC36, BRAC1/BRAC2-containing complex
subunit 36.
www.frontiersin.org January 2012 | Volume 2 | Article 5 | 3
Wang et al. Ubiquitination in kinase activation
FIGURE 2 |The role of K63-linked polyubiquitination in the activation
of canonical and non-canonical NF-κB signaling pathway. In both
canonical and non-canonical NF-κB pathways, ligand binding to receptors
results in the recruitment of theTNF receptor-associated factors (TRAFs)
to the receptors. In the canonical pathway, the recruitment of E3 ligase
TRAF6promotesits auto-polyubiquitinating and other neighboring target
proteins via K63-linked polyubiquitin chains. Unanchored free K63-linked
polyubiquitin then directly activate TAK1 kinase, which then
phosphorylates and activates IKK-β to induce NF-κB activation. In the
non-canonical pathway, TRAF3, TRAF2, and cIAP promote rapid
proteasomal degradation of NIK by the ubiquitin–proteasome system
under un-stimulated condition. Various stimuli release NIK fromTRAF3
inhibition by triggering cIAP activation byTRAF2-mediated
K63-polyubiquitination and subsequent degradation of TRAF3.
NIK-mediated-phosphorylation of p100 and its subsequent processing
promotes RelB/p52 nuclear translocation and NF-κB activation.
then recruits E3 ligase TRAF6 that functions together with dimeric
ubiquitin-conjugating enzyme complex UBC13/UEV1A to induce
its auto-polyubiquitinating and other neighboring target pro-
teins via K63-linked polyubiquitin chains (Sorrentino et al., 2008;
Yamashita et al., 2008; Martinez-Forero et al., 2009; Skaug et al.,
2009). It has been proposed that K63-linked ubiquitination chains
induced by TRAF6 serve as docking sites for TAB2,which contains
ubiquitin-binding domains (UBD; Kanayama et al., 2004; Kulathu
et al., 2009). TAB2 and TAB1 then promote the recruitment of the
serine–threonine kinase TAK1 into the complex (Kanayama et al.,
2004; Lynch and Gadina, 2004; Sun et al., 2004; Shambharkar
et al., 2007) and its subsequent activation. Activated TAK1 then
phosphorylates and activates IKK-β to promote IκB proteasomal
degradation and translocation of NF-κB members p65 and p50
into the nucleus, in turn resulting in NF-κB activation (Figure 2).
K63-linked polyubiquitination is critical in this process, because
deletion of the UBAN domain of NEMO (IKKγ) abrogates IKK
signaling. Although it was previously proposed that K63-linked
polyubiquitination of several proteins in the IL-1LR/TLR path-
ways, such as TRAF6, IRAK1, and IKKγ/NEMO, are critical for
the activation of TAK1 and IKK, a recent report provides com-
pelling evidence that none of these polyubiquitin chains on these
proteins are required forTAK1 activation (Xia et al., 2009). Instead,
unanchored free K63-linked polyubiquitin chains, which are not
conjugated to any target protein, directly activate TAK1 kinase
through binding to TAB2 (Xia et al., 2009). Two possible mech-
anisms have been proposed for the unanchored polyubiquitin
chains-mediated activationof TAK1 (Xia et al.,2009).Onepossible
explanation is that TAK1 complex is brought into close proxim-
ity by the binding of TAB2 to the polyubiquitin chain, which will
result in TAK1 autophosphorylation at Thr-187 and its activation.
Another possibility is that polyubiquitin binding induces con-
formational change of TAK1 and thus allosterically activates the
TAK1 complex. Free K63-linked polyubiquitin chains also directly
bind to IKKγ/NEMO and activate IKK, which will lead to NF-κB
activation (Xia et al., 2009).
TAK1 not only plays a role in NF-κB activation, but also in
MAPK activation in response to numerous inﬂammatory stimuli
(Wang et al., 2001; Skaug et al., 2009). TAK1 directly phospho-
rylates and activates MKK6 in an ubiquitin-dependent manner.
In addition, knockdown of TAK1 by siRNA or TAK1 inhibitors
suppresses IL-1β- and TNFα-induced IKK and c-Jun N-terminal
kinase (JNK) activation (Ninomiya-Tsuji et al., 2003;Takaesu et al.,
2003; Kanayama et al., 2004). Furthermore, inactivation of Tak1
in Drosophila melanogaster (Vidal et al., 2001; Chen et al., 2002;
Silverman et al., 2003), or deletion of Tak1 in multiple mouse cell
types abolishes IKK and MAPK activation by a variety of NF-κB
agonists (Sato et al., 2005; Shim et al., 2005; Liu et al., 2006; Wan
et al., 2006). Another study has further demonstrated a role for
ubiquitination of TAK1 as a scaffold to recruit mitogen-activated
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MEKK3 (protein kinase kinase kinase 3) and subsequently to
activate the MAP kinase pathway (Yamazaki et al., 2009).
In addition to TAK1, other kinases also play a role in NF-κB
activation. RICK (also known as RIP2), a caspase-recruitment
domain-containing kinase, plays a critical role in the NF-κB
activation in response to Nod1 and Nod2 stimulation (Ino-
hara et al., 2000; Park et al., 2007). RICK also undergoes K63-
linked ubiquitination upon Nod1 and Nod2 stimulation at K209
located within its kinase domain. This ubiquitination triggers the
oligomerization of RICK and the recruitment of TAK1 kinase,
in turn facilitating IKK activation and secretion of cytokine and
chemokine (Hasegawa et al., 2008). IRAK1, involved in TLR and
IL-1R-mediated NF-κB activation, undergoes K63-linked ubiqui-
tination upon IL-1 treatment, which is presumably ubiquitinated
byE3 ligase TRAF6 (Conze et al., 2008).Ubiquitinated IRAK1 then
recruits IKKγ and activates NF-κB signaling (Conze et al., 2008).
Stimulation of TNFR by the binding of TNFα triggers the
recruitment of TRADD,TRAF2, and RIP1 to the receptor and also
results in the activation of the canonical NF-κB pathway (Ermo-
laeva et al., 2008; Ha et al., 2009; Skaug et al., 2009; Figure 2).
Similar to TRAF6, overexpressed TRAF2 is polyubiquitinated
via K63-linked ubiquitination and is sufﬁcient to induce NF-
κB activation. However, there is functional redundancy between
TRAF2 and TRAF5, as TRAF2-deﬁcient mouse embryonic ﬁbrob-
lasts (MEFs) still activate NF-κB in response to TNFα, whereas
TRAF2/5 compound mutant MEFs is compromised in IKK acti-
vation (Yeh et al., 1997; Grech et al., 2004; Skaug et al., 2009; Zhang
et al., 2009). RIP1 is also polyubiquitinated via K63-linked chains
by TRAF2/5 and cIAP1/2 complex, which is required for TNFα-
inducedNF-κBactivation (Varfolomeev et al.,2008;Bertrand et al.,
2011). The polyubiquitin chains on RIP1 serve as docking sites to
recruit the TAK1 and IKK complexes to TNFR because the RIP1-
K377R mutant failed to recruit TAK1 and IKK to the receptor,
while retained the ability to recruit the adaptor protein TRADD
or TRAF2 (Ea et al., 2006). However, the identiﬁcation of free and
unanchored K63-linked polyubiquitin chains directly activating
TAK1 and IKK in the IL-1R/TLRpathway (Xia et al., 2009) suggests
that such a mechanism may also exist in the TNFR pathway.
Interestingly, a recent report identiﬁed a novel mechanism by
which enteropathogenic Escherichia coli NleE, a conserved bacte-
rial type-III-secreted effector, regulates ubiquitin-chain signaling
and its speciﬁcity in NF-κB activation during infection (Zhang
et al., 2012). Speciﬁcally, NleE was found to possess S-adenosyl-l-
methionine-dependent methyltransferase activity and modiﬁed a
zinc-coordinating cysteine in the Npl4 zinc ﬁnger (NZF) domains
in TAB2 and TAB3, which led to the loss of zinc ion and their
ubiquitin-chain binding activity and subsequent inactivation of
host NF-κB signaling activation.
On the other hand, the non-canonical NF-κB pathway regula-
tion depends on tightly controlled degradation of NIK. TRAF3,
TRAF2, and cIAP promote rapid proteasomal degradation of
NIK by the ubiquitin–proteasome system (UPS). Therefore, under
basal conditions, NIK protein is almost undetectable (Sasaki et al.,
2008; Vallabhapurapu et al., 2008; Zarnegar et al., 2008a,b; Razani
et al., 2010). However, various stimuli, such as CD40L and BAFF,
trigger TRAF2-mediated K63-polyubiquitination of cIAP, which
promotes K48-linked ubiquitination of TRAF3 and targets it to the
proteasome (Vallabhapurapu et al., 2008; Zarnegar et al., 2008b).
NIK is released from TRAF3 inhibition and phosphorylates and
activates IKKα, which then induces phosphorylation of p100 and
its subsequent processing by proteasome (Skaug et al., 2009; Sun,
2011). The processing of p100 is an important step in the activa-
tion of non-canonical NF-κB pathway, which not only generates
p52 transcription factor, but also induces the nuclear translocation
of RelB/p52 by releasing from its cytoplasmic localizing sequence
present in the digested fragment (Skaug et al., 2009; Sun, 2011).
Interestingly, DDR can results in NF-κB activation via K63-
linked ubiquitination as well as a novel linear ubiquitination. It
has been shown that the E3 ligase linear ubiquitin-chain assembly
complex (LUBAC), regulates NF-κB activation upon genotoxic
stress by promoting linear ubiquitination of NEMO (Niu et al.,
2011). In addition, ATM- and NEMO-dependent ELKS ubiqui-
tination coordinates TAK1-mediated IKK activation in response
to genotoxic stress (Wu et al., 2010). Furthermore, a cytoplasmic
ATM–TRAF6–cIAP1module links nuclearDNAdamage signaling
to ubiquitin-mediated NF-κB activation (Hinz et al., 2010).
Since the process of ubiquitination of target proteins is tightly
regulated by the activities of DUBs, it is conceivable that DUBs
also play critical role in the regulation of NF-κB signaling. CYLD,
a tumor suppressor which is found to be mutated in patients with
familial cylindromatosis in which affected individuals develop
multiple benign tumors of the skin appendages (Bignell et al.,
2000), shows speciﬁc DUB activity toward K63-linked polyubiq-
uitin chains, negatively regulating IKK activation. CYLD has been
shown to target TRAF6, TRAF2, and NEMO for deubiquitination
(Brummelkamp et al., 2003; Kovalenko et al., 2003; Mauro et al.,
2006; Sun, 2008, 2010; Bhoj and Chen, 2009), thus presumably
reduced their activities in NF-κB activation. Furthermore, CYLD
also cleaves free unanchoredK63-linkedpolyubiquitin chains, thus
inhibiting TAK1 and IKK activation (Xia et al., 2009). Impor-
tantly, the tumor suppressive function of CYLD has been demon-
strated in vivo using genetically engineered mouse (GEMs) model.
Cyld-deﬁcient mice are highly susceptible to chemical-induced
skin tumors, chemical-induced colitis, and colon-tumorigenesis
(Massoumi et al., 2006; Reiley et al., 2006, 2007; Zhang et al.,
2006).
Another DUB, A20, which contains an N-terminal OTU-type
DUB domain and seven C-terminal zinc ﬁngers, has been sug-
gested to play a critical role in the negative regulation of NF-κB
activation, and A20-deﬁcient mice have hyperactivation of NF-
κB pathway and multi-organ inﬂammation (Brummelkamp et al.,
2003; Kovalenko et al., 2003; Mauro et al., 2006; Sun, 2008, 2010;
Bhoj and Chen, 2009). Recent evidence also implicates that A20
also plays an essential role in human diseases (Hymowitz and
Wertz, 2010). For example, polymorphisms in the A20 locus are
associated with multiple autoimmune diseases including systemic
lupus erythematosis. In addition, A20 acts as a tumor suppres-
sor in B cell lymphoma (Compagno et al., 2009; Kato et al.,
2009) and mutated in marginal zone lymphomas (MZLs) (Novak
et al., 2009). A20 can deubiquitinate RIP1 via its OTU domain
and also act as an E3 ligase to add K48 polyubiquitin chains to
RIP1 via the ZnF region to promote its proteasomal degrada-
tion (Wertz et al., 2004). In addition, A20 has been shown to
promotedisassemblyof ubiquitination complexes in the IL-1Rand
TNFR pathways, including TRAF6–UBC13, cIAP1/2–UBC13, and
cIAP1/2–UBCH5, as well as proteasomal degradation of UBC13
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and UBCH5 (Shembade et al., 2009, 2010). Furthermore, A20 has
also been reported to block recruitment of the adaptor proteins
TRADD and RIP1 to TNFR (He and Ting, 2002), and to promote
lysosomal degradation of TRAF2 (Li et al., 2009). Interestingly,
A20 is recently shown to inhibit IKK activation through direct and
non-catalytic mechanism (Figure 2). Speciﬁcally, A20 can bind
to the unanchored polyubiquitin chain via its ZnF7 domain and
interacts with IKKγ/NEMO, which results in an impairment of
TAK1-mediated phosphorylation of IKK. Importantly, the cat-
alytic Cys 103 residue of A20 is not required for the inhibition of
IKK activation (Bosanac et al., 2010; Skaug et al., 2011).
Recently, it has been demonstrated that E3 ligase ITCH and
CYLD formed a complexwhich can sequentially cleave K63-linked
ubiquitin-chain and catalyzes K48-linked ubiquitination to deac-
tivate TAK1 and terminate NF-κB signaling (Ahmed et al., 2011),
providing an example of how K48 and K63-linked ubiquitinations
are closely linked and can be differentially utilized to control kinase
activation and deactivation.
K63-UBIQUITINATION PLAYS AN IMPORTANT ROLE IN Akt KINASE
ACTIVATION
Protein kinases play a pivotal role in signaling transduction cas-
cade, and they act as signalingmediators to convey the extracellular
clues, such as growth factors and cytokines, from the outside of the
cells to the nucleus by inducing protein phosphorylation (Hynes
and MacDonald, 2009; Klein and Levitzki, 2009). The level of
phosphorylation of a target protein is counteracted by the activity
of phosphatase. Protein kinases are also subjected to phosphory-
lation, which regulates their activities and expressions. Recently,
emerging evidence suggests a critical role for K63-linked ubiqui-
tination in the regulation of kinase activation (Yang et al., 2009,
2010a,b). Here we will focus on the regulatory function of K63-
linked polyubiquitination in kinase activation using AKT as an
example. AKT (also known as PKB) is a serine/threonine protein
kinase,which is a keystone in growth factor and cytokine-mediated
signaling cascade (Datta et al., 1999; Brazil et al., 2002; Cantley,
2002; Gonzalez and McGraw, 2009; Yang et al., 2010a). Giving that
Akt regulate numerous biological functions, such as cell growth,
survival, cell migration, and metabolism, by phosphorylating sev-
eral downstream effectors, the activity of Akt must be stringently
controlled. Aberrant Akt activation is observed in various human
cancers, and importantly,Akt1,Akt2, andAkt3 isoforms are found
to be overexpressed in human cancers (Staal, 1987; Cheng et al.,
1992, 1996; Bellacosa et al., 1995; Nakatani et al., 1999; Stahl et al.,
2004). Recent studies show that Akt1 mutations are observed in
a subset of human cancers and are associated with Akt hyperac-
tivation (Carpten et al., 2007; Kim et al., 2008a; Malanga et al.,
2008; Mohamedali et al., 2008; Askham et al., 2010; Shoji et al.,
2009; Zilberman et al., 2009). The role of Akt in cancer devel-
opment has been supported by numerous animal tumor models.
For example, Pten+/− mice with aberrant Akt activation develop
multiple tumors, which can be inhibited by Akt1 deﬁciency (Di
Cristofano et al., 2001; Chen et al., 2006). In addition, the prostate-
speciﬁc expression of constitutively active Akt1 in mice leads to
prostate intraepithelial neoplasia (Majumder et al., 2003, 2004).
Accordingly, these results highlight the critical role of the PI3K/Akt
pathway in cancer development.
Ubiquitination has been shown to regulate Akt protein degra-
dation. Several E3 ligases, such as CHIP (carboxyl terminus of
Hsc-70 interacting protein), BRCA1, and TTC3, have been shown
to target AKT for ubiquitination and subsequent proteasome
degradation (Dickey et al., 2008; Xiang et al., 2008; Suizu et al.,
2009; Toker, 2009). In addition, mTORC2-mediated phosphory-
lation of Akt at T450 also regulates Akt stability as Sin1 deﬁciency
or mTOR knockdown results in reduced T450 phosphorylation
and increased Akt ubiquitination and degradation (Facchinetti
et al., 2008).
Recently, TRAF6 has been identiﬁed as a unique E3 ligase for
Akt and induces K63-linkedAkt ubiquitination, in turn facilitating
Akt membrane recruitment and subsequent Akt T308 phospho-
rylation and activation (Yang et al., 2009, 2010a). The notion is
supported by the fact that primaryMEFs deﬁcient for Traf6 display
profound defects in Akt membrane recruitment and activation in
response to various stimuli such as growth factors and cytokines.
The ubiquitination of Akt occurs on the K8 and K14 residues
within the PH (pleckstrin homology) domain of Akt. Notably,Akt
K8R and Akt K14R mutants display defects in Akt ubiquitination,
correlatedwith the impairment of Aktmembrane recruitment and
T308 phosphorylation, suggesting thatAkt ubiquitination plays an
important role in Akt membrane recruitment and activation.
Analysis of K8Rmutant of Akt reveals that the regulation of Akt
membrane recruitment byAkt ubiquitination does not result from
its impact on the PIP3 binding. It is known that Akt membrane
localization is essentially dependent on its binding to phospho-
inositol (3,4,5) trisphosphate (PIP3) in the plasma membrane
(Brazil et al., 2002; Varnai et al., 2005). The K14R Akt mutant
fails to bind to PIP3, as the K14 residue is within the PIP3 binding
pocket. However, the K8 residue is not within the PIP3 binding
pocket (Bellacosa et al., 1998; Rong et al., 2001; Carpten et al.,
2007) and there is no difference in the binding to PIP3 between
theAkt K8Rmutant and thewild-type (Wt)Akt (Yang et al., 2009).
One Akt mutant (E17K), found in a subset of human can-
cers, displays higher PIP3 binding, membrane localization, and
activation (Brazil et al., 2002; Varnai et al., 2005). Interestingly,
this cancer-associated Akt mutant also displays a hyperubiqui-
tination of Akt, and the blocking of this hyperubiquitination
profoundly impairs Akt membrane localization, phosphorylation,
and activation (Carpten et al., 2007; Yang et al., 2009). These
results suggest that mutation of E17 residue to lysine residue
in Akt results in not only hyperubiquitination but also hyper-
PIP3 binding, and both of these events appear to contribute to
the constitutive membrane localization and activation of Akt.
Collectively, these results demonstrate that TRAF6-mediated Akt
ubiquitination is relevant and important for human cancers.
Along this line, another Akt mutation E49K has been recently
identiﬁed in bladder cancer, which also displays Akt hyperphos-
phorylation and activation compared to WtAkt (Askham et al.,
2010). Given this Akt mutation is located in the PH domain of
Akt but not in the PIP3 binding pocket, we speculate that this
mutation may not affect Akt binding to the PIP3. Since this Akt
mutant gains an additional lysine residue, it is very likely that
such mutation may also results in hyperubiquitination of Akt,
in turn contributing to its hyperactivation and hyper-oncogenic
potential.
Frontiers in Oncology | Molecular and Cellular Oncology January 2012 | Volume 2 | Article 5 | 6
Wang et al. Ubiquitination in kinase activation
Currently, it remains unclear how the K63-linked ubiquitina-
tion of Akt results in its recruitment to plasma membrane and
subsequent activation. One possibility is that TRAF6-mediated
polyubiquitination of Akt may increase its binding to PIP3 on
the membrane (Figure 3). However, it may be not the case, since
the Akt K8R mutant, which shows an impairment in Akt ubiqui-
tination, membrane recruitment and activation, displays similar
binding afﬁnity to PIP3 as WtAkt does (Yang et al., 2009), suggest-
ing that other mechanisms contribute to ubiquitination-mediated
Akt membrane recruitment and activation. It has been shown that
TCL1 family proteins formheterodimerwithAkt and promoteAkt
dimerization, in turn augmenting Akt activation (Teitell, 2005).
Therefore, another possibility is that K63-polyubiquitination of
Akt may enhance the formation of TCL1–Akt complex and Akt
dimerization, thus promoting Akt membrane localization andAkt
activation (Figure 3). Furthermore, since K63-linked polyubiqui-
tin chains have been proposed to serve as docking sites for many
signaling molecules, it is highly possible that K63-ubiquitination
of Akt enhances its binding to membrane bound adaptor pro-
tein containing ubiquitin-binding property, thereby facilitating
Akt membrane localization and activation (Figure 3). More works
will be required to further dissect these possibilities.
TARGETING UBIQUITINATION/DEUBIQUITINATION
PATHWAYS FOR THERAPY
Ubiquitination and deubiquitinationmediated through the E3 lig-
ases and DUBs regulate the activities and functions of a large
amount of protein, including tumor suppressors and oncogenes
important for cell proliferation, apoptosis, and tumorigenesis.
Importantly, the important roles of these proteins in tumorigene-
sis are supported by their frequent deregulations in human cancer
and by mouse tumor models to reveal their important roles in
cancer development. Therefore, targeting these proteins may have
important therapeutic implications for the treatment of human
cancer. Efforts have been invested to target the proteasome sub-
units (the proteolytic 20S subunit and the regulatory 19S subunit),
and E3 ubiquitin ligase, and DUBs.
Bortezomib, an inhibitor proteasome 20S subunit, has been
approved by the FDA for the treatment of multiple myeloma
(Adams and Kauffman, 2004; Bold, 2004). Recently, the small
molecule b-AP15, which inhibits the activity of two 19S
regulatory-particle-associatedDUBs,ubiquitinC-terminal hydro-
lase 5 (UCHL5), and ubiquitin-speciﬁc peptidase 14 (USP14), can
induce tumor cell apoptosis that is insensitive to TP53 status and
overexpression of the apoptosis inhibitor BCL2. Furthermore, b-
AP15 inhibits tumor progression in four different in vivo solid
tumor xenograft models, including FaDu squamous carcinoma,
HCT-116 colon carcinoma, Lewis lung carcinomas (LLCs), ortho-
topic breast carcinoma (4T1), and also inhibits organ inﬁltration
in one acute myeloid leukemia model (C1498 leukemia; D’Arcy
et al., 2011).
Many E3 ligases have been shown to play an oncogenic role
in tumorigenesis, therefore, E3 ubiquitin ligases, which confer
substrate speciﬁcity, are attractive targets for human cancers. For
example, efforts have been invested on targeting HDM2, the E3
ligase for tumor suppressor p53, aiming to elevate the protein level
of p53. Nutlin 3/R7112, an inhibitor that disrupts the interaction
between HDM2 and its substrate p53, has entered clinical trials
FIGURE 3 | Ubiquitination regulates Akt stability and activation.
IGF-1-induced activation of IGF-1R promotesTRAF6 activation, which
then triggers K63-linked ubiquitination of Akt and promotes Akt
membrane recruitment and subsequent phosphorylation by PDK1 and
mTORC2. Active Akt then phosphorylates its substrates in the cytoplasm
and nucleus to exert its biological functions. E3 ligaseTTC3 has been
suggested to play a role in the termination of active Akt signaling in the
nucleus by promoting Akt ubiquitination and degradation by the
proteasome. TTC3 activity is regulated by Akt-mediated phosphorylation
at S378, thus providing a negative feedback loop for Akt inactivation. In
addition, Akt ubiquitination is promoted by CHIP or BRCA1 and leads to
Akt degradation.
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(Cohen andTcherpakov, 2010). In addition, several inhibitors that
target inhibitors of apoptosis proteins (IAPs) have also entered
clinical trials (Cohen and Tcherpakov, 2010). These inhibitors
induce the autoubiquitination and degradation of the IAPs and
promote cancer death by stimulating the TNF-α pathway (Wu
et al., 2007).
Given the critical role of TRAF6 in the regulation of Akt ubiq-
uitination, membrane localization, and activation (Yang et al.,
2009), small molecules targeting TRAF6 can suppress Akt sig-
naling and may be considered as potential or adjuvant agents
for cancer therapy. In line with this notion, TRAF6 inhibition
by shRNA knockdown reduces Akt activation in prostate cancer
cells, suppresses tumor formation in the xenograft tumor model,
and potentiates apoptosis induced by chemotherapy agents (Yang
et al., 2009). Therefore, TRAF6 can be considered as a potential
therapeutic target for human cancer. In addition to small mole-
cules inhibitors for TRAF6, miR-145, and miR-146a have shown
to repress TRAF6 protein translation and display a potent tumor
suppressive effect on restricting the formation of primary and
metastatic breast cancer (Hou et al., 2009; Hurst et al., 2009; Star-
czynowski et al., 2010; Yuan et al., 2010). Therefore, miR-145 and
miR-146a can be applied as another strategy to target TRAF6 for
cancer treatment.
Deubiquitinating enzymes are another class of potential drug
targets for cancer treatment. DUBs have been shown to play
an important role in the regulation of the stability of many
oncoproteins by counteracting the activity of E3 ligase. USP7
(ubiquitin-speciﬁc protease 7), which deubiquitinates HDM2, can
lead to increased levels of HDM2 and decreased levels of p53.
Therefore, inhibitors for USP7 will promote HDM2 degradation
and p53 accumulation. Interestingly, as USP7 silencing stabi-
lizes p53 and enhances its activity, small molecular inhibitors for
USP7 are expected to suppress cancer cell growth. As expected,
a novel USP7 inhibitor indeed induces p53-dependent apopto-
sis by stabilizing p53 (Colland et al., 2009). USP20, also called
VDU2 (von Hippel–Lindau deubiquitinating enzyme 2) stabilizes
hypoxia-inducible factor 1α (HIF-1α; Li et al., 2005),which is over-
expressed in many human cancers. Therefore, targeting USP20
can induce degradation of HIF-1α and be a potential drug target
for human cancer. Furthermore, many transcription factors have
been demonstrated to be overexpressed and play potent onco-
genic functions in tumorigenesis, such as Myc (Pelengaris et al.,
2002), CyclinD1 (Musgrove et al., 2011) and inhibitors of DNA
binding (ID; Hasskarl and Munger, 2002). However, it has been
well-accepted that it is difﬁcult to target transcription factors with
small molecules since they lack enzymatic activity, although there
is a report that small molecule has been designed to target Bcl-6 in
mouse model for cancer therapy (Cerchietti et al., 2010). Targeting
Myc is recently demonstrated to be very effective in the treatment
of human cancers (Adhikary and Eilers, 2005; Soucek et al., 2008;
Herold et al., 2009). In addition, inactivation of Cyclin D1 can
abolish breast cancer development driven by oncogenic Ras or
Neu (Lee et al., 2000; Yu et al., 2001). Further, IDs overexpression
is observed in a broad range of dedifferentiated primary human
malignancies, such as pancreatic carcinoma and neuroblastoma
(Perk et al., 2005). Since many of these oncogenic transcrip-
tion factors are short-lived oncoproteins undergoing fast turnover,
therapeutic strategies by targeting their corresponding DUBs will
be an alternative approach, which will lead to rapid degradation
of these oncoproteins. USP28, USP2, USP1, Dub3, and USP9x
have been shown to play an important role in stabilizing onco-
genic signals, such as Myc (Popov et al., 2007), Cyclin D1 (Shan
et al., 2009), and IDs (Williams et al., 2011) and CDC25A (Pereg
et al., 2010),MCL-1 (Opferman andGreen, 2010; Schwickart et al.,
2010) respectively. Therefore, small molecules inhibitors to tar-
get these DUBs are theoretically possible to design and to target
these oncogenic transcription factors indirectly. Future experi-
ments using small molecule inhibitors to target these DUBs in
preclinical mouse tumor models may provide in vivo evidence
that targeting the DUBs can be ideal therapeutic strategies for the
treatment of human cancers.
CONCLUDING REMARKS
A large amount of recent studies in the area of ubiquitination
study have revealed several novel roles of ubiquitination in signal-
ing transduction pathways involved in a broad range of biological
functions, such as DDR, NF-κB activation, and kinase activation.
Ubiquitination can play a distinct role in the regulation of pro-
tein fate, depending on which type of the polyubiquitin chains
formedwithin the proteins (Figure 1).Mono-ubiquitination plays
a role in endocytosis, protein transport, DNA repair, and histone
regulation. K48-linked polyubiquitination signals mainly target
proteins for proteasome-dependent protein degradation, whereas
K63-linked ubiquitination serves as a scaffold for protein/protein
interaction, in turn regulating the localization and activity of
protein kinase. In addition, a novel type of linear polyubiquiti-
nation plays a role in the NF-κB activation. It is anticipated that
other novel functions on this posttranslational modiﬁcation will
be uncovered in the near future.
As strong evidence has demonstrated an important role for
ubiquitination in cancers, efforts to speciﬁcally target this pathway
with small molecules inhibitors have now been actively investi-
gated. Proteasome inhibitor Bortezomib has been approved to be
used in the treatment of multiple myeloma. Several small mol-
ecule inhibitors targeting E3 ligases have entered clinical trials,
such as inhibitors for HDM2 and IAPs. In addition, efforts have
been invested to target DUBs and small molecule inhibitors have
been developed and demonstrated efﬁcacy in the treatment of
human cancer.We anticipate to see more and more small molecule
inhibitors targeting this pathway will be developed and eventually
utilized for the treatment of human cancers.
However, there still remains several outstanding questions and
warrant for future investigations. Currently only a few E3 lig-
ases are able to trigger K63-linked ubiquitination. Will more
such E3 ligases be discovered in the genome? As many pro-
teins can undergo both K48- and K63-linked ubiquitination, it
remains to be determined how the E3 ligases and DUBs coordi-
nate to regulate signaling activation for protein kinases. A recent
report on ITVH–CYLD sheds light on how K48- and K63-link
ubiquitination/deubiquitination are closely coupled to activate
and inactivate TAK1 to tightly control the activation of NF-κB
signaling pathway. In addition, it remains largely unknown for
the roles of the novel linear polyubiquitin chains in the regula-
tion of target protein function. Moreover, much work is needed
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to determine the mechanisms for the regulation of linear vs.
branch polyubiquitination and how the ubiquitination regulates
the localization and activation of protein kinase. Furthermore,
a deeper mechanistic understanding of ubiquitination and deu-
biquitination and kinase regulation by ubiquitin remains as an
important challenge for this ﬁeld. In addition, we need to under-
stand how substrate binding and activity of ubiquitination and
DUBs are regulated. Addressing all these important questions will
lead to comprehensive understanding of the complicated mode
of ubiquitination and deubiquitination in regulating signaling
transduction pathways.
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